您当前的位置:国际号刊-月刊 > 知网目次 > 生物科学 >
MedComm(国际刊号)

MedComm(国际刊号) 知网目次

基本信息
  • 主管单位:

  • 主办单位:

    四川省国际医学交流促进会与Wiley

  • 国际刊号:

    2688-2663

  • 国内刊号:

  • 学科分类:

    生物科学

  • 字数:

    -

  • 有无基金:

     

  • 周期:

    国际号刊-月刊

  • 特殊属性:

    外文期刊

联系信息
  • 电话:

  • 邮箱:

    editorial@med-comm.orgmedcomm@med-cens.org(官网邮箱)

  • 复合因子:

    0

  • 综合因子:

    0

  • 收录:

    知网目次

  • 级别:

期刊简介

《MedComm(国际刊号)》期刊已被查看:

更新频次

单位占比

一作占比

投稿指南

1、该刊只有国际刊号!

2、投稿方式:在线投稿。

3、官网网址:

https://onlinelibrary.wiley.com/journal/26882663

(微信公众号信息)

4、投稿系统:https://mc.manuscriptcentral.com/medcomm

5、主办单位官网:https://www.scimea.cn/

(四川省国际医学交流促进会)

6、官网邮箱:editorial@med-comm.org(编辑部)

medcomm@med-cens.org(编辑部)

7、出刊日期:月刊,每月出版1期。

8、官方微信公众号:四川省国际医学交流促进会(scimea)

2022年3月18日星期五

MedComm简介

MedComm 是由中国科学院院士魏于全教授亲自操刀的又一优秀生物医学期刊。魏院士2016年创办的一流学术期刊Signal Transduction and Targeted Therapy(简称STTT),2020年影响因子18.187,位于SCI期刊JCR分区Q1区,全球生物化学和分子生物类期刊排名第5、细胞生物学类期刊排名第11。我们有理由相信MedComm 潜力无限,未来可期,成为高水平的国际期刊。

MedComm 是2020年由世界顶级出版集团Wiley出版的生物医学英文期刊(https://onlinelibrary.wiley.com/journal/26882663),目前已被ESCI、DOAJ、BIOSIS Previews等知名数据库收录,大部分论文PubMed也已收录。MedComm 竭诚欢迎生物医学领域的科研工作者、医生、研究生积极投稿。

MedComm 编委团队由英国牛津大学James Henderson Naismith教授(英国皇家科学院院士、英国皇家爱丁堡科学院院士)、耶鲁大学Günter P. Wagner教授(美国国家科学院院士、美国科学促进会院士、美国艺术与科学院院士)、川大华西医院生物治疗国家重点实验室魏于全教授(中国科学院院士)领导。编委团队由全球10多个国家的著名科学家构成,其中超过20%为国内外院士,60%以上为国外专家,包括宋伟宏院士、蒋华良院士、彭勇、黄灿华以及何明亮教授等著名专家教授。

创刊至今,MedComm 始终坚持高水平、国际化、严标准的办刊策略,所有刊载内容均经过严格的同行评审,专业高效的编辑团队管理,得到了国内外同行学者的广泛认可。MedComm 收到来自全球范围内顶尖大学和研究机构的高水平稿件。目前已在线发表80余篇论文,包括Biomaterials 主编Kam. W. Leong院士、英属哥伦比亚大学宋伟宏院士、南阿拉巴马大学Gary A. Piazza教授、多伦多大学Masoud Mozafari教授、哈佛医学院Wenjun Deng教授、美国圣约翰大学的陈哲生教授、天津医科大学姚智、第三军医大学叶丽林、浙江大学王福俤等国内外多位院士与教授的文章。MedComm 由衷地感谢期刊作者、审稿人、编辑和读者的巨大贡献, MedComm 将再接再厉,发表更多高质量的论文,更好地服务于全球的读者和作者。

《MedComm》投稿指南

【官网信息】

Author Guidelines

1. SUBMISSION

Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.

Once the submission materials have been prepared in accordance with the Author Guidelines, manuscripts should be submitted online at  https://mc.manuscriptcentral.com/medcomm

Click here for more details on how to use ScholarOne.

Data protection:

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.

Preprint policy:

Please find the Wiley preprint policy here.

This journal accepts article previously published on preprint servers.

MedComm will consider for review articles previously available as preprints. Authors are requested to update any pre-publication versions with a link to the final published article. Authors may also post the final published version of the article immediately after publication.

For help with submissions, please contact: editorial@med-comm.org or medcomm@med-cens.org

2. AIMS AND SCOPE

MedComm is a peer-reviewed, online open access journal that publishes the pioneer works providing novel insights into all aspects of medicine on the basis of novelty, timeliness and significance on human health. The journal emphasizes on original findings that advances the understanding of pathogenesis or improves the diagnosis and treatment of human disease. Interdisciplinary studies utilizing approaches of molecular biology, cell biology, chemistry, pharmacology or material science to address the issues of clinical, basic and translational medicines are particularly encouraged.

MedComm is interested in the topics including but not limited to clinical medicine, molecule diagnostics, epigenetics/genetics, cell biology, drug discovery, evolutionary medicine, nanotechnology or artificial intelligence. Clinical and experimental advances that provide the disease characteristics, pathogenic mechanism or medical techniques are focused by the journal.

Topics of interest include, but are not limited to:

Epigenetics, genomics, proteomics and metabonomics

Non-coding RNA in disease

Cell senescence and cell death

Cellular signal transduction

Gene therapy and Gene editing

Cancer immunology and Immunotherapy

Structural Biology, chemical genomics and drug discovery

High-definition imaging

Artificial intelligence in medicine

Stem cells and Regenerative medicine

Nanomedicine and drug delivery system

Early disease diagnosis and biomarkers

Clinical trials evaluating new treatments for cancer or other diseases

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

Original article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make significant contribution to the scientific knowledge in biomedical areas. Typically, the research will provide insight into an as yet unknown mechanism or poorly understood process, constitute a highly significant contribution to our understanding of biomedicine, and be of general interest to the biomedicine community. Research article will typically be 6000 words in length, with up to 8 figures and tables in total, and no limitation on the number of references.

Review, including systematic reviews and meta-analyses, is typically written by leading experts in the filed within the journal’s scope. Reviews papers help specialists to keep up with the current state of knowledge in a specific research area and provide informative message for non-specialists. Reviews aim to be a critical and concise overview of the most recent advances in a specific research field. Reviews will typically be no limitation on words in length, with up to 8 figures and tables in total, and no limitation on the number of references.

Letter to the Editor provides the rapid and concise report of a novel discovery that is brief in nature and should be of general interest to the field of biomedicine. Letters will typically be 1200 words in length excluding, references, figures and tables, with up to 1 figures and tables in total, and no more than 10 references.

Highlights aims to point the MedComm readership to the latest novel findings published in other high-impact journals. Research Highlight should contain no more than 1200 words in length excluding, references, figures and tables, up to 10 references. and 1 display item.

Editorials are the most important statement and opinions of global opinion leaders in relevant specialties and specially invited by the Editor, but unsolicited material may be considered. Please approach the Editorial Office (editorial@med-comm.org or medcomm@med-cens.org) before submitting this material. Editorials have a limit of 1,000 words, with up to 2 figures and tables in total and no more than 5 references.

Perspectives discuss published findings and ideas from a personal viewpoint. They are more forward looking and /or speculative than Reviews. Perspectives can be submitted either by the invitations from the Editors or by the authors themselves. Both types will undergo the peer-review process prior to acceptance.  Perspectives are typically 3000 words in length, with up to 4 figures and tables in total and no more than 70 references.

4. PREPARING THE SUBMISSION

Cover Letters

Cover letters are not mandatory; however, they may be supplied at the author’s discretion.

Parts of the Manuscript

The manuscript should be submitted in separate files: main text file; figures.

Main Text File

The text file should be presented in the following order:

A short informative title containing the major key words. The title should not contain abbreviations (see Wiley's best practice SEO tips);

A short running title of less than 40 characters;

The full names of the authors;

The author's institutional affiliations where the work was conducted, with   a footnote for the author’s present address if different from where the       work was conducted;

Acknowledgments;

Abstract and keywords;

Main text;

References;

Tables (each table complete with title and footnotes);

Figure legends;

Appendices (if relevant).

Figures and supporting information should be supplied as separate files.

For the benefit of the reviewers and editors, please include line numbers in your main text files.

Abstract

Please provide an abstract of 200 words containing the major keywords summarizing the article.

Keywords

Please provide three to six keywords.

Main Text

The journal uses British/US spelling; however, authors may submit using either option, as spelling of accepted papers is converted during the production process.

Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter

……

更多详情:

https://onlinelibrary.wiley.com/page/journal/26882663/homepage/author-guidelines

中国全科医学发文选摘

  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析

常见问题

  • 哪些期刊可以用来评职称?

    1、期刊要具备正规性和合法性,需在国家新闻出版总署备案,具备国内刊号(cn)。2、期刊要具备学术性,例如该期刊需被国内主流学术、数据库收录,例如被知网,万方,维普收录。具体详情可以咨询我们的客服老师为您解答。

  • 你们的服务可以保证文章被发表吗?

    期刊发表的成功与否,主要取决于文章内容的质量。期刊编辑会根据研究领域、创新性等多因素进行考量。我们会帮助您理解期刊的发表要求,助力提升发表几率,从而增加发表的机会。

  • 请问发表一篇期刊的费用是多少?

    期刊的种类繁多,其费用也各不相同。根据您的需求,将为您推荐最具性价比的期刊,让您能更便捷地找到心仪的期刊。一般来说,只要符合职称评定要求的,大多数作者都会选择性价比最高的期刊作为首选目标。

  • 如果发表不成功可以退款吗?

    如果因为我方原因导致未能发表成功,我们将全额退还相关费用。需要明确的是,稿件能否发表主要取决于期刊的独立考量。为了提升您的发表几率,我们会提供专业的指导和支持,帮助您避免拒稿,并助力提高您的稿件质量。

  • 请问文章发表需要多长时间?

    不同级别的期刊发表时间是不一样的。无论是普刊还是核心期刊,建议您提前准备。普刊需提前3-6个月,而核心期刊需提前一年左右。为确保职称评定流程顺利进行,建议您提前半年到一年进行准备,以免错过申请的最佳时机。

  • 期刊发表能加急见刊吗?

    为了确保顺利发表,建议您提前一些时间进行安排。本站仅提供投稿发表咨询服务,需要用户自己向出版商投稿且没有绿色通道,是否录用一切以出版商通知为准。